/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Agios Pharmaceuticals, Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$27.16 0.0189(1.89%) AGIO at 04 Dec 2025 04:25 PM Biotechnology
Lowest Today 27
Highest Today 27.725
Today’s Open 27.07
Prev. Close 26.98
52 Week High 62.45
52 Week Low 22.24
Day’s Range: Low 27 High 27.725
52-Week Range: Low 22.24 High 62.45
1 day return -
1 Week return -5.73
1 month return -31.35
3 month return -24.07
6 month return -19.3
1 year return -53.74
3 year return -7.88
5 year return -38.56
10 year return -

Institutional Holdings

Farallon Capital Management, L.L.C. 9.93

Vanguard Group Inc 9.78

BlackRock Inc 8.32

Bellevue Group AG 6.18

BB Biotech AG Ord 6.05

Erste Asset Management GmbH 4.00

COMMODORE CAPITAL LP 4.00

T. Rowe Price Associates, Inc. 3.91

State Street Corp 3.36

Macquarie Group Ltd 3.27

Vanguard Total Stock Mkt Idx Inv 3.11

Macquarie Small Cap Core I 2.46

Geode Capital Management, LLC 2.42

Vanguard Small Cap Index 2.42

iShares Russell 2000 ETF 2.34

Armistice Capital, LLC 2.01

Paradigm Biocapital Advisors LP 1.97

Bank of America Corp 1.93

Dimensional Fund Advisors, Inc. 1.90

Citadel Advisors Llc 1.86

Caligan Partners LP 1.84

JPMorgan Chase & Co 1.77

BNP Paribas Investment Partners SA 1.75

Rock Springs Capital Management LP 1.70

T. Rowe Price Health Sciences 1.69

Deutsche Bank AG 1.59

DWS Vermögensbildungsfonds I LD 1.39

Vanguard Small Cap Growth Index Inv 1.37

Vanguard Institutional Extnd Mkt Idx Tr 1.07

SPDR® S&P Biotech ETF 1.04

BNP Paribas Health Cr Innovtr Cl Cap 0.99

Fidelity Small Cap Index 0.98

iShares Russell 2000 Value ETF 0.86

BNP Paribas US Small Cap ClassicC 0.69

US Small-Cap Growth II Equity Comp 0.65

JPM Global Healthcare C (acc) USD 0.64

Vanguard Explorer Inv 0.62

iShares Biotechnology ETF 0.57

Fidelity Extended Market Index 0.54

T. Rowe Price Integrated US SmCapGrEq 0.50

Market Status

Strong Buy: 3

Buy: 3

Hold: 3

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 1573.31 M

PB Ratio 1.264

PE Ratio 0.0

Enterprise Value 715.11 M

Total Assets 1663.20 M

Volume 1201115

Company Financials

Annual Revenue FY24:36498000 36.5M, FY23:24030000 24.0M, FY22:14240000 14.2M, FY21:41409 0.0M, FY20:203196000 203.2M

Annual Profit FY24:32333000 32.3M, FY23:21322000 21.3M, FY22:12536000 12.5M, FY21:40703 0.0M, FY20:200391000 200.4M

Annual Net worth FY24:673725000 673.7M, FY23:-219622000 -219.6M, FY22:-74555000 -74.6M, FY21:1604715000 1604.7M, FY20:-335218000 -335.2M

Quarterly Revenue Q3/2025:12880000 12.9M, Q2/2025:12455000 12.5M, Q1/2025:8726000 8.7M, Q4/2024:10730000 10.7M, Q3/2024:8964000 9.0M

Quarterly Profit Q3/2025:11201000 11.2M, Q2/2025:9494000 9.5M, Q1/2025:7641000 7.6M, Q4/2024:9470000 9.5M, Q3/2024:8181000 8.2M

Quarterly Net worth Q3/2025:-103433000 -103.4M, Q2/2025:-112020000 -112.0M, Q1/2025:-89289000 -89.3M, Q4/2024:-96523000 -96.5M, Q3/2024:947915000 947.9M

Fund house & investment objective

Company Information Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 486

Industry Biotechnology

CEO Mr. Brian M. Goff M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow